Wróć

Wybierz swój region

Corporate

Europa:

Flaga Albania Albania Flaga Bośnia i Hercegowina Bośnia i Hercegowina Flaga Bułgaria Bułgaria Flaga Chorwacja Chorwacja Flaga Cypr Cypr Flaga Czarnogóra Czarnogóra Flaga Czechy Czechy Flaga Dania Dania Flaga Estonia Estonia Flaga Hiszpania Hiszpania Flaga Kosowo Kosowo Flaga Litwa Litwa Flaga Łotwa Łotwa Flaga Luksemburg Luksemburg Flaga Macedonia Macedonia Flaga Niemcy Niemcy Flaga Polska Polska Flaga Portugalia Portugalia Flaga Rumunia Rumunia Flaga Serbia Serbia Flaga Słowacja Słowacja Flaga Słowenia Słowenia Flaga Szwajcaria Szwajcaria Flaga Szwecja Szwecja Flaga Turcja Turcja Flaga Węgry Węgry Flaga Wielka Brytania Wielka Brytania Flaga Włochy Włochy

Azja:

Flaga UAE UAE Flaga Hong Kong Hong Kong Flaga Kuwejt Kuwejt Flaga Liban Liban

Afryka:

Flaga RPA RPA

Umów konsultację o krwi pępowinowej

Umawiam

Skontaktuj się z nami już dziś!

Chcesz dowiedzieć się więcej o naszych usługach? Uzupełnij poniższy formularz, a my skontaktujemy się z Tobą jak najszybciej, aby udzielić Ci wszelkich potrzebnych informacji oraz odpowiedzieć na Twoje pytania.

    Uprzejmie informujemy, że dane osobowe podane w formularzu będą przetwarzane przez Polski Bank Komórek Macierzystych Sp. z o.o. („PBKM”) z siedzibą w Warszawie, Al. Jana Pawła II 29 w celu kontaktu telefonicznego w związku z udzieleniem informacji na temat usługi.

    Zestawienie leczonych pacjentów

    Terapie
    komórkami macierzystymi

    Terapie komórkami macierzystymi

    Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).

    Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.

    Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.

    Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.

    Data aktualizacji: 06.2026

    Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord

    Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
    Lp. Źródło Typ źródła Wskazanie Obszar medycyny Rok podania Terapia Kraj Wiek odbiorcy
    5401 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 35
    5402 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 70
    5403 Apheresis Allogeneic Multiple Myeloma Hematology 2019 Standard Therapy Germany 57
    5404 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 41
    5405 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 60
    5406 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 68
    5407 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 65
    5408 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 63
    5409 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 65
    5410 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 66
    5411 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 57
    5412 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 65
    5413 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 67
    5414 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 64
    5415 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 70
    5416 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 64
    5417 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 66
    5418 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 68
    5419 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 58
    5420 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 59
    5421 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 72
    5422 Apheresis Autologous Multiple Myeloma Hematology 2019 Standard Therapy Germany 65
    5423 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 62
    5424 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 55
    5425 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 62
    5426 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 14
    5427 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 61
    5428 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 61
    5429 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 75
    5430 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 45
    5431 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 70
    5432 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 72
    5433 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 69
    5434 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 45
    5435 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 40
    5436 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 65
    5437 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 72
    5438 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 50
    5439 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 59
    5440 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 66
    5441 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 61
    5442 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 42
    5443 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 68
    5444 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 65
    5445 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 56
    5446 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 63
    5447 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 62
    5448 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 64
    5449 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 42
    5450 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 68
    5451 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 61
    5452 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 68
    5453 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 62
    5454 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 66
    5455 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 66
    5456 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 67
    5457 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 4
    5458 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 56
    5459 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 66
    5460 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 62
    5461 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 61
    5462 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 61
    5463 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 63
    5464 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 44
    5465 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 45
    5466 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 33
    5467 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 66
    5468 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 65
    5469 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 49
    5470 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 69
    5471 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 71
    5472 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 25
    5473 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 42
    5474 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 46
    5475 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Poland 65
    5476 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Germany 49
    5477 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Germany 66
    5478 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Germany 64
    5479 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Germany 67
    5480 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2019 Standard Therapy Germany 66
    5481 Apheresis Allogeneic Myelodysplastic Syndrome – Raeb Hematology 2019 Standard Therapy Poland 21
    5482 Apheresis Allogeneic Myelodysplastic Syndrome – Raeb Hematology 2019 Standard Therapy Poland 16
    5483 Apheresis Allogeneic Myelodysplastic Syndrome; Myeloproliferative Neoplasms Overlap Hematology 2019 Standard Therapy Germany 64
    5484 Apheresis Allogeneic Myelofibrosis Hematology 2019 Standard Therapy Poland 46
    5485 Apheresis Allogeneic Myelofibrosis Hematology 2019 Standard Therapy Poland 62
    5486 Apheresis Allogeneic Myelofibrosis Hematology 2019 Standard Therapy Poland 47
    5487 Apheresis Allogeneic Myelofibrosis Hematology 2019 Standard Therapy Poland 33
    5488 Apheresis Allogeneic Myelofibrosis Hematology 2019 Standard Therapy Poland 45
    5489 Apheresis Allogeneic Myelofibrosis Hematology 2019 Standard Therapy Poland 43
    5490 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2019 Standard Therapy Poland 66
    5491 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2019 Standard Therapy Poland 69
    5492 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2019 Standard Therapy Poland 63
    5493 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2019 Standard Therapy Poland 61
    5494 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2019 Standard Therapy Poland 61
    5495 Apheresis Allogeneic Myeloma Multiplex Hematology 2019 Standard Therapy Poland 45
    5496 Apheresis Allogeneic Myeloma Multiplex Hematology 2019 Standard Therapy Poland 62
    5497 Apheresis Autologous Myeloma; Amyloidosis Hematology 2019 Standard Therapy Germany 47
    5498 Apheresis Autologous Natural Killer / T-Cell-Non-Hodgkin-Lymphoma Hematology 2019 Standard Therapy Germany 32
    5499 Apheresis Allogeneic No Data Hematology 2019 Standard Therapy Poland 43
    5500 Apheresis Allogeneic No Data Hematology 2019 Standard Therapy Poland 20